Safeguarding India Amidst the EG.5 Variant: A Pragmatic Outlook

Dear Editor,

The landscape of the ongoing battle against the COVID-19 pandemic has once again shifted with the emergence of a new variant (EG.5), sending ripples of concern across the globe. As of August 7th, 2023, 7354 EG.5 sequences from 51 different nations had been submitted to GISAID. China accounts for the biggest percentage of EG.5 sequences (30.6%, 2247 sequences). Other nations with at least 100 sequences include the Republic of Korea (14.1%), Japan (11.1%), and the United States of America (18.4%). ¹ This new EG.5 variant, has sparked a flurry of discussions and analyses, as it carries FLip mutations (The L455F and F456L mutations are colloquially referred to as “FLip mutations” due to their capacity to interchange the positions of 2 specific amino acids denoted as F and L within the spike protein structure.) that seem to confer a notable advantage in evading immune responses compared to its predecessor, XBB.1.9.2. The dynamics of this variant have set the stage for a comprehensive evaluation of its potential impact on public health. The genetic changes exhibited by EG.5 are causing researchers to closely scrutinize its behavior. This variant, However, laboratory experiments have revealed that XBB+L455F+F456L (a rare subvariant of XBB containing both FLip mutations have displayed a remarkable ability to elude immune detection. This newfound prowess has raised concerns among experts, with Eric Topol of Scripps Research in California highlighting the potential for a more troublesome evolution of the virus in the near future. ²

Epidemiological week 29 (17-23 July 2023) saw a 17.4% global prevalence of EG.5. This represents a significant improvement over the data published 4 weeks earlier (week 25, 19 to 25 June 2023), when the prevalence of EG.5 was 7.6% worldwide. ¹ Although the situation is not anticipated to escalate into an “omicron event” akin to a surge in transmission and adverse outcomes due to an influx of new mutations, the genetic transformations observed in XBB+L455F+F456L are undeniably indicative of an ongoing evolution of SARS-CoV-2. This perspective, as outlined by Topol, underscores the significance of monitoring the trajectory of this variant in the weeks to come.

From the Indian standpoint, the implications of this variant’s rise are far-reaching. In India, EG.5.1 first appeared in Maharashtra back in May. According to health professionals, COVID variants XBB.1.16 and XBB.2.3 are still prevalent in Maharashtra. ³ The scenario in the United Kingdom, where the EG.5.1 subvariant, affectionately dubbed “Eris,” triggered a health alert, serves as a stark reminder of the potential for rapid proliferation. As concerns amplify, statistical data becomes increasingly imperative. The growth in cases linked to EG.5, though currently modest, indicates a trajectory that merits vigilant attention.

In the realm of proactive measures, the development and distribution of new vaccines offer a glimmer of hope. Renowned pharmaceutical entities such as Moderna, Novavax, and Pfizer have tailored their boosters to target XBB.1.5, a close relative of the ancestral strain XBB.1.9.2. ⁴ These iterations are anticipated to provide heightened protection against the EG.5 lineage, signifying a strategic move to stay ahead of viral evolution. Additionally, antiviral drugs like nirmatrelvir/ritonavir (Paxlovid) continue to demonstrate effectiveness against the evolving threat.

The situation at hand necessitates a balance between vigilance and restraint. While the emergence of XBB+L455F+F456L and EG.5 warrants heightened attention, it is crucial to retain a nuanced perspective. ⁵ Research-driven insights into the behavior of this variant will guide strategies that align with its evolution. As the world collectively adapts to changing circumstances, continued communication, data-sharing, and global collaboration remain instrumental in navigating the complex terrain of viral mutations.

The rise of new variants present a new chapter in the ongoing struggle against the pandemic. This variant’s FLip mutations introduce a layer of complexity that demands thorough analysis and rapid responses. While the immediate concern is not a dramatic surge akin to the omicron variant, the implications of this evolutionary trajectory demand earnest attention. Robust data-driven strategies, coupled with the fortification of our defense mechanisms, will undoubtedly be pivotal in addressing the challenges posed by this emerging variant. With the use of molecular data and immune mechanisms, the advent of new or more specific vaccines is not farsighted.